@FiercePharma: #Pfizer extricates itself from investor lawsuit with $400M payment. More | Follow @FiercePharma
@EricPFierce: Pfizer settles investor suit over marketing probe of Bexta for $400M. Story | Follow @EricPFierce
> The U.K.'s cost-effectiveness watchdogs gave their final blessing to Alexion's ($ALXN) rare disease drug Soliris (eculizumab), which is, at £340,200 per year, the most expensive drug ever approved by the agency. Report
> India's Ranbaxy Laboratories, soon to be sold to Sun Pharmaceuticals, swung back to a loss for the most recent quarter as sales waned and a one-time tax payment ate into earnings. Report
> Novo Nordisk ($NVO) says it's not deterred from investing in the Russian pharma market despite the country's economic turndown and conflict in the Ukraine. Report
> Novartis ($NVS) is in talks to sell a former research site in Horsham, England, to the University of Brighton. Report
Medical Device News
@FierceMedDev: ICYMI yesterday: AdvaMed: China's push for hospitals to buy domestic devices all talk, no action. Article | Follow @FierceMedDev
@EmilyWFierce: Find out which med tech companies scored key device approvals in 2014 in @FierceMedDev's latest special report. Feature | Follow @EmilyWFierce
> St. Jude gains FlexAbility approval, lays out 2015 sales growth strategy. Article
> Illumina soars 32% in Q4 with sales of next-gen sequencing system. News
Biotech News
@FierceBiotech: Pfizer's hunting for safe M&A bets, not high-risk pipeline deals. Article | Follow @FierceBiotech
@JohnCFierce: $GSK and $NVS get EU clearance for the Big Swap -- selling some assets along the way. More | Follow @JohnCFierce
@DamianFierce: News to me: $AMGN's PCSK9 blocker will sell as Repatha, which sounds a bit like a mid-sized sports utility vehicle. | Follow @DamianFierce
> Interested in biotech financing in the U.K.? Story
> Wells Fargo dispatches biotech banker to Cambridge/Boston supercluster. News
Drug Delivery News
> PARI snags FDA approval for cystic fibrosis nebulizer platform. News
> Microneedle patch maker Zosano Pharma raises $50M in IPO. Article
> Nanomed lifetime is an important aspect of delivery potential, scientists say. More
> Shire's intrathecally delivered candidate for Hunter syndrome gets FDA's Fast Track Designation. Report
> Australian team developing novel formulation to deliver common diabetes drug. Article
Diagnostics News
> Myriad settles patent feud with Invitae, Pathway Genomics over BRCA technology. News
> Roche nabs FDA OK for drug-resistant bacteria test. More
> Sequenom strikes a deal with Cypher Genomics to develop advanced noninvasive prenatal test. Report
> Sera Prognostics taps industry niche with preterm birth risk test. Story
> Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. Article
Pharma Marketing News
> Novartis revs up Cosentyx launch as it braces for a psoriasis pricing war. News
> Express Scripts takes a bow for cutting $4B off hep C drug spending. Article
> Auryxia differentiation strategy, check. Next, Keryx has to persuade prescribers. Story
> Bayer, J&J launch new stroke study to pump up payer-persuading Xarelto data. More
> Valeant bets big on the Super Bowl with $4.5M toe-fungus ad. Article
> And Finally... Actavis ($ACT) CEO Brent Saunders talked M&A, including its latest deal for generics maker Auden Mckenzie, with Maria Bartiromo on Fox Business. Video